Business Description
HCW Biologics Inc
NAICS : 541714
SIC : 2834
ISIN : US40423R2040
Total Employee Number:
36Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 1.14 | |||||
Debt-to-EBITDA | -17.68 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.88 | |||||
Beneish M-Score | 1.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -84.9 | |||||
3-Year EBITDA Growth Rate | 44.4 | |||||
3-Year EPS without NRI Growth Rate | 16.8 | |||||
3-Year FCF Growth Rate | 34.9 | |||||
3-Year Book Growth Rate | -72.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 44.12 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.12 | |||||
9-Day RSI | 23.55 | |||||
14-Day RSI | 34.16 | |||||
3-1 Month Momentum % | 568.16 | |||||
6-1 Month Momentum % | 59.82 | |||||
12-1 Month Momentum % | -57.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.09 | |||||
Quick Ratio | 0.09 | |||||
Cash Ratio | 0.06 | |||||
Days Sales Outstanding | 2.73 | |||||
Days Payable | 116498.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -54.3 | |||||
Shareholder Yield % | -31.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.21 | |||||
Operating Margin % | -96.1 | |||||
Net Margin % | -34.75 | |||||
EBITDA Margin % | -5.64 | |||||
FCF Margin % | -173.71 | |||||
OCF Margin % | -173.71 | |||||
ROA % | -8.65 | |||||
ROIC % | -20.38 | |||||
3-Year ROIIC % | 23.44 | |||||
ROC (Joel Greenblatt) % | -5.19 | |||||
ROCE % | -53.47 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.58 | |||||
PB Ratio | 0.84 | |||||
Price-to-Tangible-Book | 0.84 | |||||
EV-to-EBIT | -10.74 | |||||
EV-to-EBITDA | -32.84 | |||||
EV-to-Revenue | 1.85 | |||||
EV-to-Forward-Revenue | 1.87 | |||||
EV-to-FCF | -1.07 | |||||
Price-to-GF-Value | 0.1 | |||||
Earnings Yield (Greenblatt) % | -9.31 | |||||
FCF Yield % | -166.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HCWB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HCW Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.593 | ||
| EPS (TTM) ($) | -56.76 | ||
| Beta | 4.0976 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 363.13 | ||
| 14-Day RSI | 34.16 | ||
| 14-Day ATR ($) | 1.280128 | ||
| 20-Day SMA ($) | 6.881299 | ||
| 12-1 Month Momentum % | -57.07 | ||
| 52-Week Range ($) | 1.499999 - 44.099999 | ||
| Shares Outstanding (Mil) | 1.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HCW Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HCW Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 16:45 | In 133 days | ||
| Second quarter earnings results for 2026 | 2026-08-18 | In 45 days | ||
| 0.166667:1 Stock Split | 2026-06-30 | 5.26 (-15.77%) | ||
| General meeting for 2026 | 2026-06-15 10:00 | 7.68 (-2.29%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.02 (-4.67%) | ||
| Annual report for 2025 | 2026-03-31 | 2.17 (-7.70%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 2.17 (-7.70%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 16:45 | 14.94 (-3.86%) | ||
| Second quarter earnings results for 2025 | 2025-08-18 | 24.54 (-5.32%) | ||
| General meeting for 2025 | 2025-06-17 10:00 | 32.10 (+0.19%) |
Show
Entries
HCW Biologics Inc Frequently Asked Questions
What is HCW Biologics Inc(HCWB)'s stock price today?
The current price of HCWB is $4.30. The 52 week high of HCWB is $44.10 and 52 week low is $1.50.
When is next earnings date of HCW Biologics Inc(HCWB)?
The next earnings date of HCW Biologics Inc(HCWB) is 2026-08-18 Est..
Does HCW Biologics Inc(HCWB) pay dividends? If so, how much?
HCW Biologics Inc(HCWB) does not pay dividend.
Guru Commentaries on NAS:HCWB
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics | 2025-09-18 |
Articles on HCW Biologics Inc
No articles.
Headlines
See More- 1
Jun 30, 2026
HCW Biologics regains Nasdaq compliance
Seeking Alpha • 7:49am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers